期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 10, 页码 2318-2326出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1397660
关键词
Small lymphocytic lymphoma; chronic lymphocytic leukemia; gene mutations; prognostic factors; clinicobiological characteristics
资金
- Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII) (International Cancer Genome Consortium-Chronic Lymphocytic Leukemia Genome Project)
- red Tematica de Investigacion del Cancer (RITCC) of the ISCIII [RD12/0036/0023, RD12/0036/0036, SAF2015-64885-R]
- red Tematica de Investigacion del Cancer (RITCC) of the ISCIII (Fondo de investigaciones sanitarias) [PI16/00420]
- Fellowship Program of Gilead Espana [GLD15/00288]
- Generalitat de Catalunya Suport Grups de Recerca AGAUR [2014-SGR-795, 2014-SGR-668]
- Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII) (FIS-PMP15)
Small lymphocytic lymphoma (SLL) is considered as the non-leukemic form of presentation of chronic lymphocytic leukemia (CLL). We have compared the features, genomic alterations, and outcome of 890 patients with CLL and SLL. One hundred and thirteen patients presented as SLL and more frequently had unmutated-IGHV, CD38(high), ZAP-70(high), CD49d(high), thorn12, alterations in genes of NOTCH1, cell cycle, RNA metabolism, and NFkB pathways than CLL. During the follow-up, 46% of SLL patients developed CLL. Time to first treatment (TTFT) was shorter in SLL (10-year: 75% vs 62%; p = .006). Binet stage, SLL, and IGHV were independent predictive factors for TTFT. Transformation to diffuse large B-cell lymphoma was higher (10-year: 12% vs 6%; p = .003), and overall survival was shorter in SLL (10-year: 55% vs 66%; p = .004). When A0 CLL patients were excluded, only CD38 and CD49d expression, thorn12, and 10-year TTFT remained different between the SLL and CLL patients. In summary, SLL showed only minor clinicobiological differences when compared with CLL in similar clinical stages.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据